search
Back to results

Research a New Predictive Marker of Intraventricular Hemorrhage in Very Preterm Infants (HEMO PREMA)

Primary Purpose

Intraventricular Hemorrhage

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Standard cranial echography
Cord blood analysis
Sponsored by
University Hospital, Rouen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Intraventricular Hemorrhage

Eligibility Criteria

1 Day - 1 Day (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Alive preterm infants between 24 weeks gestation and 29 weeks and 6 days
  • Infants of both sexes
  • Children whose parents signed a free and informed consent after oral information by one of the study investigators
  • Exact term (pregnancy onset evaluated by the craniocaudal length or the date of the puncture in a medical assisted reproduction)
  • Children with social protection

Exclusion Criteria:

  • Maternal taking of antiplatelet therapy or anticoagulation within 48 hours of birth
  • Acquired maternal disease constituting a risk factor for neonatal hemorrhage
  • Constitutional maternal disease constituting a risk factor for neonatal hemorrhage
  • Severe fetal malformation
  • Cesarean birth after diagnosis of hydrocephalus detected in utero
  • Minors parents
  • History of mental disease,or sensory abnormality of one of the parents, which can lead to confusion about the study

Sites / Locations

  • Rouen University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

preterm infants with intracranial hemorrhage

preterm infants without intracranial hemorrhage

Arm Description

Cord blood analysis of preterm infants with radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed

Cord blood analysis of preterm infants without radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed

Outcomes

Primary Outcome Measures

tPA-PAI-1 Complex rate in cord blood
tPA-PAI-1 Complex rate in cord blood will be analysed in the 2 groups of infants

Secondary Outcome Measures

MMP-3 rate in cord blood
MMP-3 rate in cord blood will be analysed in the 2 groups of infants
PAI-1 rate in cord blood
PAI-1 rate in cord blood will be analysed in the 2 groups of infants
PDGF-CC rate in cord blood
PDGF-CC rate in cord blood will be analysed in the 2 groups of infants
675G4 / G5 G11053T PAI-1 Genetic variations sequencing
Polymorphism of specified sequence will be performed in the 2 groups of infants
A-922g eNOS Genetic variations sequencing
Polymorphism of specified sequence will be performed in the 2 groups of infants

Full Information

First Posted
March 2, 2015
Last Updated
December 6, 2016
Sponsor
University Hospital, Rouen
search

1. Study Identification

Unique Protocol Identification Number
NCT02400853
Brief Title
Research a New Predictive Marker of Intraventricular Hemorrhage in Very Preterm Infants
Acronym
HEMO PREMA
Official Title
Research a New Predictive Marker of Intraventricular Hemorrhage in Very Preterm Infants: HEMO PREMA Study
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Unknown status
Study Start Date
July 2015 (undefined)
Primary Completion Date
August 2018 (Anticipated)
Study Completion Date
August 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Rouen

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The most frequent complications in premature infants are neurological complications: intracranial hemorrhages and white matter lesions. In Epipage 2 study the incidence of severe intraventricular hemorrhages remains stable. Severe hemorrhages are associated with neurological sequelae. A recent study in humans and in animals shows the role of the complex formed by plasminogen activator (t-PA) and its inhibitor (PAI-1) in the induction of vascular fragility via stromelysin (MMP-3). FIBRINAT study in Rouen University Hospital showed a rate of complex t-PA-PAI1 probably very high in preterm infants. An other factor maturation PDGF-C induced by t-PA is associated with the vascular embrittlement. Among the few genetic factors associated with cerebral palsy include 2 SNP of PAI-1 gene and one SNP in the gene of endothelial NO synthase. The hypothesis is that a high rate of the complex t-PA-PAI-1 in cord blood could be a high risk of intracranial hemorrhage in preterm infants and provide predictive of their occurrence. The rates of MMP-3, PDGF-C and PAI-1 free in cord blood, and the polymorphism of PAI-1 gene and eNOS could separately or associated with the main criterion to identify predictive of hemorrhages. The main objective is to search a rate difference of the complex t-PA-PAI-1 in cord blood of preterm infants (before 30 weeks of gestation) that would predict intracranial hemorrhage coming in the first days of life. The secondary objectives are Evaluate potential marker risk of high levels of MMP-3, PAI-1 free, and PDGF-CC Search in both groups the presence of alleles -675G4 / G5 and 11053 (G / T) of the PAI-1 gene and -922 (A / G) of the eNOS gene. 120 preterm infants will be included before 30 weeks of gestation with precise inclusion and exclusion criteria during a period of 3 years. Patients will be divided into two groups according to whether they will or not showed intracranial hemorrhage (detected by ultrasound J5-J7). The complex rate tPA-PAI-1, PAI-1 free, MMP-3 and PDGF-C will be measured. The comparison between the two groups will be carried out using statistical tests. Comparison of the presence of the alleles -675 4G and 11053T the PAI-1 gene or -922G eNOS gene between the two groups will be performed. The demonstration of this hypothesis would permit to identify children from birth in whom the immediate implementation of preventive treatment of bleeding is desirable.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intraventricular Hemorrhage

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
preterm infants with intracranial hemorrhage
Arm Type
Experimental
Arm Description
Cord blood analysis of preterm infants with radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
Arm Title
preterm infants without intracranial hemorrhage
Arm Type
Active Comparator
Arm Description
Cord blood analysis of preterm infants without radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
Intervention Type
Device
Intervention Name(s)
Standard cranial echography
Intervention Description
Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
Intervention Type
Procedure
Intervention Name(s)
Cord blood analysis
Intervention Description
Cord blood will be collected during deliverance and analysed
Primary Outcome Measure Information:
Title
tPA-PAI-1 Complex rate in cord blood
Description
tPA-PAI-1 Complex rate in cord blood will be analysed in the 2 groups of infants
Time Frame
day 1
Secondary Outcome Measure Information:
Title
MMP-3 rate in cord blood
Description
MMP-3 rate in cord blood will be analysed in the 2 groups of infants
Time Frame
day 1
Title
PAI-1 rate in cord blood
Description
PAI-1 rate in cord blood will be analysed in the 2 groups of infants
Time Frame
day 1
Title
PDGF-CC rate in cord blood
Description
PDGF-CC rate in cord blood will be analysed in the 2 groups of infants
Time Frame
day 1
Title
675G4 / G5 G11053T PAI-1 Genetic variations sequencing
Description
Polymorphism of specified sequence will be performed in the 2 groups of infants
Time Frame
day 1
Title
A-922g eNOS Genetic variations sequencing
Description
Polymorphism of specified sequence will be performed in the 2 groups of infants
Time Frame
day 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
1 Day
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Alive preterm infants between 24 weeks gestation and 29 weeks and 6 days Infants of both sexes Children whose parents signed a free and informed consent after oral information by one of the study investigators Exact term (pregnancy onset evaluated by the craniocaudal length or the date of the puncture in a medical assisted reproduction) Children with social protection Exclusion Criteria: Maternal taking of antiplatelet therapy or anticoagulation within 48 hours of birth Acquired maternal disease constituting a risk factor for neonatal hemorrhage Constitutional maternal disease constituting a risk factor for neonatal hemorrhage Severe fetal malformation Cesarean birth after diagnosis of hydrocephalus detected in utero Minors parents History of mental disease,or sensory abnormality of one of the parents, which can lead to confusion about the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lénaïg DONVAL, MD
Email
lenaig.donval@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Julien BLOT
Email
julien.blot@chu-rouen.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stéphane MARRET, Pr
Organizational Affiliation
UH Rouen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rouen University Hospital
City
Rouen
ZIP/Postal Code
76031
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lénaïg DONVAL, MD

12. IPD Sharing Statement

Learn more about this trial

Research a New Predictive Marker of Intraventricular Hemorrhage in Very Preterm Infants

We'll reach out to this number within 24 hrs